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Multiple nucleoside resistance involves specific mutational patterns of the HIV-1 pol gene that are independent of the
classic mutations conferring resistance to individual dideoxynucleosides. These include a cluster of five mutations in the
reverse-transcriptase (RT) coding region (A62V, V75I, F77L, F116Y, and Q151M) generally referred to as multidrug resistance
(MDR) mutations, and insertions of one or several amino acid residues between codons 67 and 70 of RT, a flexible region
joining two antiparrallel b sheets (b3–b4 insertions). The objectives of this study were (i) to determine the prevalence of
multidrug resistance genotypes (MDR mutations and b3–b4 insertions) in a cohort of 632 patients who were extensively
pretreated with anti-HIV drugs and not responding to their current antiretroviral therapy, and (ii) to analyze the association
of multidrug resistance genotypes with other resistance mutations in the RT and protease genes. Among viruses sequenced
from these patients, 15 (2.4%) of them contained an insertion and 2 (0.3%) contained a deletion in the b3–b4 finger subdomain
of RT. In 9 cases, the insertion was associated with a D67S, G, or E mutation. In addition, we identified 13 (2.1%) viruses
harboring specific MDR mutations (mainly Q151M and/or A62V, V75I, F116Y). Interestingly, the A62V mutation was found in
6 of the 15 strains with an insertion, whereas the other MDR mutations were not observed in insertion mutant strains.
Especially high levels of resistance to zidovudine were observed for viruses with a b3–b4 insertion in the background of
A62V, L210W, and T215Y. Otherwise, MDR mutations and b3–b4 insertions were found in association with the classic
mutations conferring resistance to zidovudine, lamivudine, nonnucleoside RT inhibitors, and protease inhibitors, according to
treatment history. Finally, we observed a genome with a deletion of codon 70 associated with a Q151M MDR mutation. These
data suggest that the emergence of HIV-1 multidrug resistance, which may occur in various genetic contexts, poses a
challenging problem in formulating treatment strategies. © 2000 Academic PressINTRODUCTION
The infection cycle of HIV-1 is dependent on the func-
tions of reverse transcriptase (RT), a virally encoded
polymerase which converts the viral RNA genome into
proviral DNA prior to its integration into the host genomic
DNA. It is a heterodimer of a 66- and 51-kDa subunit,
termed p66 and p51. Crystallographic data have revealed
that both subunits form a right-hand-like structure con-
sisting of several subdomains designated palm, fingers,
and thumb subdomains that cooperate to form the tem-
plate-binding cleft (Kohlstaedt et al., 1992; Jacobo-Molina
et al., 1993; Huang et al., 1998; Sarafanios et al., 1999).
The high variability of HIV-1 is due to the high mutation
rate of RT which is a poorly processive enzyme (Kew et
al., 1998). The processivity of polymerase refers to the
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310average number of deoxynucleotides incorporated per
template-primer encounter and reflects the accuracy of
the RNA-dependent DNA polymerization. It has been
proposed that the low processivity of retroviral RT has
been evolutionarily conserved to facilitate the strand
transfer reaction, which is a key step in retroviral DNA
synthesis (Pathak and Temin, 1990). Considering the lack
of 39 exonuclease proofreading activity of RT, the poor
processivity of RT may be the principal cause for the high
rate of nucleotide substitutions, deletions, insertions,
and recombination events observed for HIV-1 RT. Upon
treatment with nucleoside analog RT inhibitors, HIV-1
variants exhibiting resistance-associated mutations in
the RT gene are selected and the replication of these
strains is a major cause of treatment failure (Hirsch et al.,
1998). Some of these mutations, often referred to as MDR
(multidrug resistance) mutations, may induce a broad
resistance phenotype to various nucleoside analogs.
MDR mutations include A62V, V75I, F77L, F116Y, and
Q151M (Maeda et al., 1998). Recently, it has been shown
that resistance to multiple nucleoside analogs could also
result from the insertion of a short sequence in the
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311MULTIDRUG RESISTANCE GENOTYPES OF HIV-1 RTb3–b4 hairpin loop of the finger domain of RT (Tamalet et
l., 1998), although it is unclear whether the insertion
nduces resistance by itself or only when combined to
ther mutations such as T215Y (Winters et al., 1998;
T
Amino Acid Changes in the RT Protein of Insertio
Note. Insertions are shown in bold type with the nucleotide
correspond to wild-type codons. Deletions are figured as (2)
indicated after the patient’s initials (e.g., BS 02/97 means that
patient BS in February, 1997).arder et al., 1999). The b3–b4 subdomain of HIV-1 RT is 1irectly involved in the interaction of the enzyme with its
ubstrates (i.e., the template-primer complex and the
ncoming dNTP), thereby controlling the processivity of
he RNA-dependent DNA polymerization (Arion et al.,
tion, and MDR Mutant HIV-1 Compared to HXB2
nce indicated under the corresponding amino acid. Dashes
ates when the viruses were recovered from the patients are
s has been sequenced from a plasma sample obtained fromABLE 1
n, Dele
seque
. The d996; Arnold et al., 1995; Kew et al., 1998; Tantillo et al.,
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312 TAMALET ET AL.1994). The aim of the present study was to document the
presence of multidrug resistance genotypes in a cohort
of 632 patients under combination therapy and to ana-
lyze their association (or lack of association) with other
resistance mutations in the RT and protease genes.
RESULTS
Insertions and deletions in the b3–b4 hairpin loop of
he finger subdomain of HIV-1 RT
The genotypic analysis of plasma HIV-1 RNA from 632
atients revealed rearrangements in the RT coding re-
ion (between amino acids 67 and 70 belonging to the
b3–b4 hairpin loop) in 17 cases (Table 1). These genetic
earrangements resulted in a net deletion of one amino
cid residue (i.e., T69 for patient NC, and K70 for patient
V) or in a net gain of one or two residues in the RT
rotein. The inserted sequences were particularly en-
iched in serine (S). An additional mutation at codon D67
D67S, G, or E) was detected in 9 cases. Interestingly, the
eletion in patient NC was also associated with a D67S
utation. However, the classical D67N substitution,
hich is generally associated with resistance to zidovu-
ine, was not detected in the inserted or deleted se-
uences analyzed in this study. Most importantly, the
eletion in patient QV was associated with the major
DR mutation Q151M.
The stability of the rearrangements in the b3–b4 hair-
in loop was assessed by sequencing the RT gene from
patients at different time points over a minimal period
f 10 months (patient BS) and a maximal period of 54
onths (patient AC). In the case of patient JY, the initial
SS insertion was later replaced by SSG. This amino
cid change was due to a single mutation of codon AGT
coding for serine) leading to GGT (coding for glycine). In
act, a minor population with the amino acid SSG se-
uence could be detected first (Fig. 1), suggesting that
he SSG variant was selected from a mixture of SSS and
SG. The virtual absence of fluorescence background in
he electrophoregram shown in Fig. 1 allowed the iden-
ification of the minor G peak unambiguously. Moreover,
he presence of the minor SSG mutant at MO was con-
irmed by sequencing the complementary strand (not
hown). After 18 months, the SSG insertion was shifted
nd replaced by EGS. Then, the therapy of this patient
as stopped and the insertion was no longer detected,
hereas M41L and T215Y remained the only resistance
utations observed in the RT gene. A similar disap-
earence of the insertion was observed for patient BP
08/99) who stopped the therapy in May 1999. Yet the
nsertion mutant was detected again in November 1999,
month after the therapy was started again. Other cases
f evolution of the inserted sequence were noted for
atients AC (STG 3 SVG), DD (SSG 3 SVG) and GRSSA 3 SST). aDR mutations
MDR mutations were detected in 13 patients: A62V (3
ases), V75I (4 cases), F77L (6 cases), F116Y (7 cases),
nd Q151M (12 cases). Moreover, substitutions at some
f these positions with unusual residues were also ob-
erved: V75T (1 case) which occurs upon stavudine se-
ective pressure but rarely in vivo, and Q151L (2 cases),
which may represent an intermediate genotype which
precedes the Q151M MDR mutation. Indeed, the Q3 M
substitution requires two difficult nucleotide changes (a
double transversion) of the codon (CAG3 ATG). A single
A 3 T transversion in this codon (CAG 3 CTG) would
facilitate the process. In agreement with this hypothesis,
both Q151Q/L and Q151L/M heterozygotes could be de-
tected in patients BB and BF, respectively (Table 1). In
this latter case, the Q151L/M mixture evolved toward
Q151M. Therefore, it is tempting to speculate that the
difficult Q151M substitution can occur upon selective
pressure because the intermediate Q151L mutation is
not deleterious for the enzyme. Recent data on the com-
parative fitness of MDR resistant HIV-1 strains support
this view (Kosalaraksa et al., 1999).
Resistance mutations associated with inserted and
MDR genotypes
As shown in Table 1, the A62V MDR mutation was
present in 6 of the 15 strains with an insertion, whereas
the other MDR mutations were not observed in insertion
mutant strains. However, in one case, the Q151M muta-
tion was found in association with a deletion of codon 70
(patient QV). The major zidovudine resistance mutations,
i.e., K70R and T215Y/F, could be detected in association
with a b3–b4 insertion (4 cases for K70R, 11 cases for
215Y, and 4 cases for T215F). Similarly, these mutations
ere found in combination with MDR mutations (5 cases
or K70R, 1 case for T215Y, and 4 cases for T215F). In
ontrast, the minor L210W mutation was not observed in
FIG. 1. Emergence of the SSG inserted sequence from a mixture of
SSS and SSG sequences. The figures shows the electrophoregram
corresponding to the RT coding region (from codons 66 and 72) for
patient JY at two sequential time points (M0 and M12).ssociation with MDR mutations, whereas D67N was
T313MULTIDRUG RESISTANCE GENOTYPES OF HIV-1 RTdetected only in those strains bearing the Q151M MDR
mutation. Finally, mutations conferring resistance to non-
nucleoside RT inhibitors (K103N, V108/I, Y181C, Y188L,
and/or G190A) were found in association with MDR as
well as insertion mutations.
The pattern of resistance-associated mutations in the
protease gene (Table 2) was consistent with the treat-
ment history of the patients. Patients FC and PT, for
instance, show a D30N mutation consistent with the use
of nelfinavir in their combination therapy. Curiously, the
L10I mutation was more frequently observed in genomes
with an insertion in the RT gene than in genomes with
MDR mutations. Further studies will help to clarify
whether mutation patterns of HIV-1 RT may affect the
polymorphism of the protease gene, as recently dis-
cussed by Berkhout (1999). Finally, a rare L10Y substitu-
T
Amino Acid Changes in Protease of Insertion,tion was observed in one case (patient TK).DISCUSSION
In this study, we have analyzed the incidence of MDR
genotypes (including insertions/deletions in the b3–b4
finger subdomain of RT and MDR mutations) in a homog-
enous cohort of 632 patients with therapeutic failure. We
detected 15 (2.4%) genotypes with an insertion, 2 (0.3%)
with a deletion, and 13 (2.1%) with MDR mutations (mainly
Q151M and/or A62V, V75I, F116Y). Overall, multiresistant
genotypes (i.e., either MDR mutations or insertions) were
found in 29 (4.6%) of the viruses sequenced from the 632
patients studied. These data are in agreement with pre-
vious population studies showing an incidence of 3% for
b3–b4 insertions (De Jong et al., 1999; Ross et al., 1999;
amalet et al., 1998), and 1–2% for MDR mutations
(Shirazaka et al., 1995; Iversen et al., 1996). Moreover,
neither MDR nor b3–b4 insertions were detected in ther-
n, and MDR Mutant HIV-1 Compared to HXB2ABLE 2
Deletioapy-naive patients with primary HIV infection, supporting
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314 TAMALET ET AL.the concept that multidrug resistant viruses are selected
under antiretroviral treatment. In this respect, various
combinations of zidovudine, didanosine, zalcitabine, and
stavudine seem to precipitate the emergence of those
viruses (Larder et al., 1999; Ross et al., 1999).
The presence of a rare amino acid change at codon
67 (D67S, G, or E) associated with a b3–b4 insertion
confirms and extends previous data reported by three
laboratories (Winters et al., 1998; De Jong et al., 1999;
arder et al., 1999). In addition, one major outcome of the
resent study is the finding of a statistically significant
ombination of the MDR mutation A62V and a b3–b4
insertion (P , 0.01). This mutation, when associated
ith Q151M, modifies the hydrophobic core of the finger
ubdomain of HIV-1 RT in order to adjust the orientation
f methionine 151 (Huang et al., 1998). In the same way,
nsertions and/or deletions in the b3–b4 hairpin loop are
likely to affect the dNTP-binding pocket through subtle
conformationnal changes. Therefore, our data raise the
interesting hypothesis that the A62V mutation may help
the enzyme to accommodate the insertion in the b3–b4
airpin loop. This would lead to a reorganization of the
NTP-binding pocket exhibiting a decreased affinity for
ome nucleoside analogs. In agreement with this hy-
othesis, phenotypic assays with recombinant mutant RT
Table 3) showed that mutation A62V, in the background
f T215Y, L210W, and a SSS insert, increased the level of
idovudine resistance by more than 10-fold (Larder et al.,
999). A high level of resistance to zidovudine was also
eported by De Jong et al. (1999) for a virus with both a
b3–b4 insertion (SSG) and mutation A62V in the RT gene
Table 3). In order to determine whether mutation A62V
ould act in synergy with a b3–b4 insertion to increase
the level of zidovudine resistance, population-based re-
combinant isolates were prepared from patient plasma
virus and assayed for susceptibility to zidovudine. As
shown in Table 3, high levels of resistance (.1500-fold)
were observed for the viruses obtained from patients BP
and GB, with a b3–b4 insertion in the background of
62V, L210W, and T215Y. Interestingly, a lower level of
esistance was observed when the insertion was com-
ined with L210W and T215Y, but not A62V (patient BR).
oderate levels of resistance were found when the
b3–b4 insertion was associated with T215F, with or with-
ut A62V (patients MP and AR, respectively). Taken to-
ether, these data suggest that the presence of a b3–b4
nsertion associated with mutations A62V, L210W, and
215Y confers a particularly high level of resistance to
idovudine.
Insertion mutants generally appear in the background
f zidovudine resistance mutations, especially T215Y. In-
eed, viral constructs that contained both the T215Y
utation and an insertion showed higher IC50 to the RT
inhibitors than the constructs containing only the inser-
tions (Winters et al., 1998; Larder et al., 1999). Previousodeling studies did not allow an explanation of how theidovudine resistance mutations act in concert with the
nsertion to increase the level of resistance (Larder et al.,
999). It is possible that the additional effect of the T215Y
utation on the magnitude of resistance induced by the
nsertion may be due to a hydrophobic-mediated reorga-
ization of residues lining the dNTP-binding pocket, es-
ecially Asp 113. However, it is interesting to note that in
wo patients of the present study, the insertion was found
n association with a wild genotype at codon 215 (pa-
ients AC and SR). In one of these cases (patient AC), the
nsertion was exclusively associated with three muta-
ions that confer resistance to nonnucleoside inhibitors
f RT (i.e., K103N, Y181C, and G190G/A). Therefore, the
ppearance of b3–b4 insertions can, in rare cases, occur
n a genome devoid of zidovudine resistance mutations,
uggesting that zidovudine therapy is not a prerequisite
or subsequent development of insertions. This result is
n agreement with a recent study by Ross et al. (1999).
inally, it should be emphasized that the MDR mutation
151M is never observed in association with a b3–b4
nsertion (P , 0.001). In only one case, this mutation
as present in combination with a deletion of codon 70.
o our knowledge, this is the first time that such an
ssociation is described. Overall, these data further il-
ustrate the complexity of genetic rearrangements that
ay potentially affect the conformation of the dNTP-
inding pocket in the context of multidrug therapy.
From an evolution point of view, the emergence of the
SG variant from a mixed population enriched in ge-
omes with the SSS insertion (patient JY, Fig. 1 and Table
) suggests a selective advantage for SSG. Indeed, phe-
otypic assays from Winters et al. (1999) have shown that
virus with a SSG insert is significantly more resistant to
idovudine than a virus with a SSS insert (Table 3). In
ddition, biochemical studies have shown that the SSS
ariant has a lower RT activity than the SSG variant,
uggesting that the SSS/SSG switch may represent a
ompensatory mechanism allowing a gain of fitness
Boyer et al., 1999). Thus, a fine “tuning” of the inserted
equence may be necessary to optimize the orientation
f the b3–b4 hairpin loop, and this may be achieved by
he appearance of additional mutations within the insert
r nearby the dNTP-binding pocket (see Huang et al.,
998, for a discussion of “tuning” effects in HIV-1 RT).
rom an enzymatic point of view, insertions in the b3–b4
finger subdomain have been shown to increase the pro-
cessivity of the polymerase (Kew et al., 1998). Namely,
the enrichment of the loop in G and S residues may
respectively contribute to enhance the mobility of the
peptide chain and its capacity to hydrogen bond to the
substrates. By strengthening its interactions with the
template and the dNTP, the mutant RT may become more
processive (Kew et al., 1998) and may have a selectively
decreased affinity for the triphosphorylated analogs.
That most mutations conferring resistance to zidovudine
increase the processivity of RT strongly supports this
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315MULTIDRUG RESISTANCE GENOTYPES OF HIV-1 RThypothesis (Arion et al., 1996, 1998). Alternatively, it has
een proposed that resistance to zidovudine could also
artially result from an increased pyrophosphorolytic
leavage of chain-terminated viral DNA by the mutant RT,
molecular mechanism which may be interpreted as a
ype of proofreading activity expressed by the mutant RT
Arion et al., 1998). In this context, the increased proces-
ivity of the mutant RT may represent a compensatory
echanism for the increased reverse reaction rate.
CONCLUSIONS
Genetic rearrangements in the b3–b4 hairpin loop of
he finger subdomain of RT and MDR mutations are still
ncommon changes of HIV-1 RT (prevalence ,5%)
merging in extensively treated patients. These geno-
ypes, which appear in various genetic contexts and are
enerally associated with therapeutic failure, pose a
hallenging problem in formulating treatment strategies.
he location of these mutations in the three-dimensional
tructure of RT is consistent with a conformationnal ef-
ect on the dNTP-binding pocket leading to cross-resis-
ance to various nucleoside inhibitors of RT. From a
iagnostic point of view, one should be aware that alter-
ative genotyping technologies based on hybridization
ay fail to detect b3–b4 insertions in clinical samples
Vahey et al., 1999). Considering that the polymorphism
f RT nearby resistance codons is also a major short-
oming of these techniques (Kozal et al., 1998; Koch et
l., 1999), dye terminator cycle sequencing is probably
he more versatile and reliable technology for the detec-
ion and characterization of resistant HIV-1 strains.
MATERIALS AND METHODS
atients
A cohort of 1109 patients under combination therapy
ncluding various associations of zidovudine, lamivudine,
idanosine, d4T, nevirapine, indinavir, ritonavir, nelfinavir,
r saquinavir was followed in the reference hospitals for
IV/AIDS located in Marseille, France. A total of 3064
IV-1 pol DNA and/or RNA sequences has been ob-
ained since January 1997 and stored in a specifically
esigned database (Yahi et al., 1999). In the present
tudy mutant genotypes were examined in plasma HIV-1
NA from a subpopulation of 632 extensively treated
ubjects considered to be failing therapy (viremia greater
han 1000 HIV-1 copies/ml), and with at least three re-
istance mutations (as defined by Hirsch et al., 1998) in
he RT gene.
enotypic analysis
Genotypic resistance was evaluated by sequencing of
he RT and protease genes with the ABI PRISM dye
erminator cycle sequencing kit using Amplitaq Polymer-
se FS (Applied Biosystem) as described previously (Ta-alet et al., 1998). The direct sequencing of PCR prod-
cts gives the composition of the nucleotides most fre-
uently observed at each position and excludes the
urrent artifacts associated with cell culture and cloning.
equence products were analyzed with the Applied Bio-
ystem 377 automatic sequencing system. The se-
uences were aligned on the HXB2 RT and protease
enes with the Sequence Navigator software (Applied
iosystem). A x2 test was applied to assess the signifi-
ance of specific associations (or lack of association) of
esistance mutations.
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